

Message

From: Harrell, Jamie [Jamie.Harrell@covidien.com]
Sent: 6/7/2012 1:00:48 PM
To: #MKG - Pharma Field Sales [MKG-Pharma-Field-Sales@covidien.com]; #MKG - Dos Prod - Int. Staff (Brand) [MKG-Dos-Prod-Int.-Staff-Brand@covidien.com]
CC: Brendel, Diane [Diane.Brendel@covidien.com]; Harrell, Jamie [Jamie.Harrell@covidien.com]; Jones, Jason D [Jason.Jones@Covidien.com]; Patrick, Jeffrey [Jeffrey.Patrick@covidien.com]; Roevekamp, Jan L [Jan.Roevekamp@Covidien.com]; Schroeder, Danielle [Danielle.Schroeder@Covidien.com]; Shamel, Ronald D [Ronald.Shamel@Covidien.com]; Stamer, Jeremy [Jeremy.Stamer@covidien.com]; Swartz, Betty Jean (BJ) [bj.swartz@covidien.com]; Terifay, Terry W [Terry.Terifay@covidien.com]; Tilly, Jason [Jason.Tilly@Covidien.com]; Wickline, Ronald P [Ronald.Wickline@covidien.com]
Subject: SUMAVEL Co-promotion.docx
Attachments: image001.png; image002.png; image003.jpg; image004.jpg; SUMAVEL QA.pdf

[Description: Final-REVISED-2.0-Logo-DK-blue.png]

[cid:image003.jpg@01CD4483.A655FC70]

Field Sales Team:

As you heard earlier today, we are adding a new product to your bag! SUMAVEL(r) DosePro(r) (sumatriptan injection) is a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches. It is a great addition to our pain franchise as many of our customers treat migraines.

The main thing I want all of you to know is there is a lot of excitement - both here at Mallinckrodt and with our new collaborator, Zogenix - about our new venture to sell SUMAVEL DosePro. I hope you have that same energy and enthusiasm in the field. This co-promotion fulfills our commitment to you and the company to grow the franchise and clearly "Green Lights" our business development and licensing goal on our SP 2.0 scorecard.

Knowing many of you probably have questions, please see the attached file with a top line set of Q&As. We look forward to sharing more information as we approach Mallinckrodt's launch of our promotion of SUMAVEL DosePro in August.

Speaking of launch, mark your calendars for our National Launch Meeting the week of August 12. More information will be coming soon.

While we expect big things from this collaboration, EXALGO(r) remains our focus. As our flagship brand, continue using INSPIRE to elevate EXALGO with your target physicians and drive for success. This is YOUR time to finish out FY12 strong!

Best!
Jamie

P.S. Here's what Mark Trudeau, President, Pharmaceuticals, and Roger Hawley, Chief Executive Officer of Zogenix, said about the partnership:

Mark Trudeau:

"This agreement represents a key component of our growing pharmaceutical business as Mallinckrodt prepares to spin off from Covidien next year. We believe that the combined resources of these two companies will enable us to leverage our talented and successful sales force where it can make the most difference for prescribers and patients."

Roger Hawley:

"Adding Mallinckrodt's large sales force to the efforts of our 95 sales representatives will double our reach into prescribers of migraine products and significantly expand our sales coverage for SUMAVEL DosePro within the primary care market. The Mallinckrodt team has a track record of commercial success in the pain market, and is committed to educating their customers on the potential benefits of SUMAVEL DosePro as an exciting treatment option. Our team will remain engaged with neurologists, headache

specialists and other key migraine prescribers, while working closely with Mallinckrodt at the field level to effectively drive sales."

[Description: MALCOV tail.jpg]

COVIDIEN, COVIDIEN with logo and Covidien logo are U.S. and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company or their respective owners. (c) 2012 Covidien.